DN4 questionnaire

Key takeaways

The DN4 questionnaire is a 10-item validated tool for screening neuropathic pain with a cut-off score of ≥4/10.

It combines 7 patient-reported symptom descriptors with 3 clinical examination findings, administered by a trained clinician.

DN4 offers ~83% sensitivity and ~90% specificity, making it a reliable screening tool for differentiating neuropathic from non-neuropathic pain.

Pabau’s customizable digital forms allow practices to embed validated assessment tools like the DN4 into patient intake workflows.

The DN4 questionnaire is a validated 10-item screening tool that helps clinicians identify neuropathic pain in 3 to 5 minutes. Developed by Bouhassira et al. (2005), it has strong psychometric properties. Sensitivity is about 83% and specificity about 90% at a cut-off score of 4 or higher.

This guide covers the DN4’s structure, step-by-step administration, and scoring rules. It also explains how to fit the tool into your practice. Plus, it offers a free downloadable PDF ready to print or embed in your intake system.

What is the DN4 questionnaire?

The DN4 questionnaire (Douleur Neuropathique 4 questions) is a validated 10-item clinician-administered screening tool for identifying neuropathic pain. Bouhassira et al. developed and published the DN4 in the journal Pain in 2005. It has since become one of the most widely used screening instruments in pain management, neurology, and general practice, including physical therapy practices.

Its purpose is to help clinicians differentiate neuropathic pain, caused by nerve injury or dysfunction, from non-neuropathic pain such as musculoskeletal or inflammatory pain. The tool is straightforward to administer. A clinician conducts a brief patient interview to assess 7 symptom descriptors, then performs a focused clinical examination to check for 3 specific neurological findings.

The entire process takes 3 to 5 minutes, making it practical for busy practice settings. The DN4 is particularly valuable when neuropathic pain is suspected, such as in diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy, or spinal cord injury.

From a regulatory standpoint, the DN4 is not a diagnosis-confirming test but rather a screening tool that supports clinical decision-making. Its development was rigorously validated against established neuropathic pain criteria, and it has since been translated into multiple languages and validated in diverse healthcare settings.

How to administer the DN4

Administering the DN4 follows a clear two-part structure: Patient interview (Part 1) followed by clinical examination (Part 2). Here are the five core steps:

1. Conduct the patient interview: Ask the patient about 7 possible symptoms: Burning, painful cold, electric shocks, tingling, pins and needles, numbness, and itching. For each symptom, record a “yes” (1 point) or “no” (0 points) based on the patient’s report. This part is purely subjective and relies on the patient’s own experience.
2. Perform the clinical examination: With the patient undressed to expose the affected area, examine for three specific neurological findings. Test for hypoesthesia (reduced sensation) to light touch, hypoesthesia to pinprick, and allodynia (pain triggered by a stimulus that normally does not cause pain). Again, record 1 point for “yes” and 0 points for “no”.
3. Calculate the total score: Add all 10 items together. The score ranges from 0 to 10. No additional weighting or subscale calculations are needed. It is simply the sum of all yes/no responses.
4. Interpret the result using the cut-off: A score of 4 or higher (≥4/10) indicates that neuropathic pain is likely present. A score below 4 suggests non-neuropathic or non-predominantly neuropathic pain, though clinical judgment should always guide final assessment.
5. Document and follow up: Record the DN4 score in the patient’s medical record as part of the assessment documentation. Use the result to inform further investigation (e.g. nerve conduction studies, imaging) and treatment planning. If neuropathic pain is likely, consider referral to a neuropathy specialist or escalation of pain management.

Accurate administration depends on training. Clinicians should know the exact wording of each symptom descriptor and the palpation technique for the examination findings. Consistency matters across multiple administrations, whether you’re screening for change over time or comparing outcomes across your practice. That depends on standardized application.

Who benefits from DN4 screening?

The DN4 questionnaire is broadly applicable across healthcare specialties wherever neuropathic pain assessment is relevant:

• Neurologists and pain specialists: DN4 is a first-line screening tool in neurology clinics, especially for peripheral neuropathy and post-herpetic neuralgia.
• General practitioners and primary care: GPs use the DN4 to screen diabetic patients, those with chronic pain, or patients with atypical pain complaints.
• Physiotherapists and occupational therapists: Musculoskeletal practitioners use DN4 to identify whether pain has a neuropathic component, informing rehabilitation strategies.
• Pain management clinics: Multidisciplinary pain teams rely on DN4 as a standardized assessment to characterize pain type before treatment planning.
• Oncology and palliative care: Screening for chemotherapy-induced peripheral neuropathy and cancer-related neuropathic pain.
• Spinal injury and rehabilitation centres: Post-injury neuropathic pain assessment and monitoring.

The DN4 is equally valuable in research settings, where its brevity and strong validation make it an ideal outcome measure for neuropathic pain trials. Any practice setting where pain is assessed benefits from a standardized, validated screening tool, from patient data collection at intake to ongoing follow-up.

Benefits of using the DN4 questionnaire

Rapid and practical: The DN4 takes 3 to 5 minutes to complete and needs no special equipment, just a small pin and light-touch testing. It fits easily into routine practice workflows without disrupting patient flow.

Validated and reliable: Published validation studies confirm sensitivity ~83% and specificity ~90%, meaning it reliably distinguishes neuropathic from non-neuropathic pain in diverse patient populations. Clinicians can trust the result as a clinical decision-making aid.

Standardized communication: The DN4 gives clinicians a structured way to document pain type, improving clarity between colleagues and during referrals. Paired with a consistent format like SOAP charting, it reduces ambiguity in pain descriptions.

Supports evidence-based treatment: Identifying neuropathic pain guides pharmacological choice (e.g. gabapentinoids, SNRIs) and non-pharmacological interventions (e.g. desensitization, nerve blocks). Incorrect pain classification can lead to ineffective or inappropriate treatment.

Audit and compliance ready: The DN4 is recognized in major pain management and neuropathy guidelines. Routine use demonstrates adherence to best practice standards and supports quality audits and regulatory reviews in healthcare settings.

DN4 scoring and interpretation

Scoring the DN4 is straightforward: Assign 1 point to each “yes” response and 0 points to each “no” response, then sum all 10 items. The total score ranges from 0 to 10.

The cut-off of ≥4/10 was established in the original validation study and has been consistently confirmed across diverse populations. However, the DN4 is a screening tool, not a diagnostic test: Clinical judgment always takes precedence. A patient with a score below 4 who presents with compelling clinical features of neuropathic pain warrants further investigation regardless of the questionnaire score.

Psychometric properties: The DN4 achieved sensitivity of about 83% and specificity of about 90% at the ≥4 cut-off in the original Bouhassira 2005 study.

Later validations tested these figures against confirmed neuropathic pain diagnoses documented in patient records, and the results held steady across multiple languages and patient populations. This makes the DN4 one of the most reliable brief screening tools available.

DN4 compared to other neuropathic pain screening tools

Several validated screening tools exist for neuropathic pain. The DN4 stands out for its brevity and balanced structure, but understanding alternatives helps clinicians choose the best tool for their context.

The DN4 is favored in many European and global settings for its balance of brevity and reliability. It combines subjective symptoms with objective examination findings and has a strong multilingual validation base.

painDETECT is more common in German-speaking regions, while LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) is shorter but slightly less sensitive. Most pain management and neurology guidelines recognize all three as acceptable screening tools, and local practice often determines which one clinicians choose.

Language versions and instrument licensing

The DN4 has been translated and validated in numerous languages, including Spanish, German, French, Italian, Portuguese, Chinese, Dutch, Polish, and many others. Each language version has undergone formal psychometric validation to ensure that the tool’s reliability and validity are maintained across linguistic and cultural contexts.

The DN4 is managed and licensed through ePROVIDE and Mapi Research Trust, an international organization that maintains standardized instruments for clinical research and practice. Practices and healthcare facilities can access validated translations and learn about licensing terms via the ePROVIDE platform.

For most routine clinical use, the DN4 is available at no cost, though formal research studies may require explicit permission depending on the study’s scope.

How Pabau supports neuropathic pain assessment documentation

Administering the DN4 generates structured clinical data that should be recorded in the patient’s medical record. Pabau’s AI-assisted documentation and customizable digital forms let practices embed validated assessment tools like the DN4 directly into patient intake workflows. This cuts paperwork and improves data-capture consistency.

With Pabau, clinicians can:

• Create a digital DN4 form that patients complete on a tablet or the practice portal before their appointment.
• Automatically calculate and store the score in the patient’s record.
• Set automated reminders to re-administer the DN4 at follow-up visits.
• Generate reports that track neuropathic pain screening trends across the patient population.

Automated workflows can trigger follow-up actions, such as scheduling a specialist referral or sending post-visit educational materials, based on the DN4 score. This helps ensure no patient with likely neuropathic pain is missed.

Streamline clinical assessment with Pabau

Embed validated screening tools like the DN4 into your patient intake, automate follow-up workflows, and keep all assessment data organized in one secure clinical record.

Book a demo

Conclusion

Screening for neuropathic pain doesn’t need to be complicated. Run the DN4 during a normal patient interview and exam, then apply the ≥4 cut-off. That gives you a defensible basis for referral or treatment decisions in under five minutes.

What matters most is consistency. A score means little if every clinician in your practice interprets the symptom descriptors differently. Build the exact wording into your intake process, rather than leaving it to memory.

Download the PDF above to get started, or move the DN4 into a digital form so every score sits in the patient’s record automatically. Book a demo to see how Pabau turns validated tools like the DN4 into a repeatable part of your intake workflow.

Continue your research

Need a fast neurological exam reference? Neuro exam cheat sheet summarizes the key tests clinicians use alongside DN4 findings.

Assessing fall risk in older patients? Falls efficacy scale measures a patient’s confidence during everyday activities.

Documenting care after a stroke? CVA nursing care plan template structures neurological monitoring and goals.

Frequently asked questions